Dear colleagues and friends, We are delighted to announce that the 10th annual WuXi Global Forum will be held virtually on January 10, 2022 alongside the J.P. Morgan Healthcare Conference. […]
WXPress is your window into the world of WuXi AppTec and our global partners. WXPress gives you an insider’s perspective on our collaborative efforts to develop innovative medicines that improve the lives of patients.
Dr. Robert Beardsley, Founder and Chief Operating Officer at Galera Therapeutics, shares his company’s R&D vision and pipeline, aimed at improving treatments and outcomes for cancer patients. Recently, Galera’s lead […]
Celebrate SMA Awareness with us! Stuart Peltz (Founder and CEO, PTC Therapeutics) shares his perspectives on the dynamics of R&D in the context of the journey that led to the […]
In the past few years, the field of cell and gene therapy has witnessed major breakthroughs. It has become one of the hottest fields in the biotech industry, with the […]
WuXi AppTec is convening and working together with experts, from our company and around the world, for ongoing analysis of the COVID-19 pandemic. We are also partnering with other industry […]
Please click on the banner image above to watch the dialogue. “I believe by 2040, we will begin to demonstrate significant efforts that will prevent this disease, where we prevent […]
Please click on the banner image above to watch the dialogue. “What we understand is that these diseases begin very early in life. They don’t suddenly occur when you’re in […]
Please click on the banner image above to watch the dialogue. “The most important thing that we can accomplish in the next number of years, and I certainly hope we […]
Please click on the banner image above to watch the dialogue. “We’re in the age of precision medicine. I think we need to move into precision health promotion, precision medical […]
This complimentary webinar will convene leading physicians, drug developers, patients and advocates. These experts will discuss the latest advances in the development of transformative medicines for hemophilia, including gene therapy and next generation technologies.
In honor of World Neurofibromatosis (NF) Awareness Month, the WuXi AppTec community is proud to join the millions around the world working to enhance our understanding of this rare disease.
WuXi AppTec hosted the second online forum on the COVID-19 pandemic, titled “Harnessing Our Collective Power”, which attracted 2487 viewers via Zoom and 112,000 viewers via live streaming from 37 countries and regions.
This 18-speaker forum created a strong platform for professionals within industry and academia to discuss the challenges seen in the global management of the COVID-19. Topics such as: diagnosis, therapeutic intervention, vaccine development and global preparedness were keenly discussed in conjunction with patient-focused solutions.
During Day two, we took a look at health beyond therapy alone. Tomorrow’s healthcare will go far further than prescribing drugs or performing surgery, it’s about bringing in the wider […]
The opening day agenda focused on novel medicines. We explored how science, technology, and entrepreneurship is driving a new age of geographically dispersed innovators, operating internationally to “bridge productivity” and […]
WuXi Healthcare Forum 2019 Meeting Tomorrow’s Health Challenges March 5-6, 2019 | St. Regis Shanghai For registration details, please visit the Forum website. We are at the dawn of a […]
Now in its eighth year, the WuXi Global Forum at the J.P. Morgan Healthcare Conference brings together thousands of leaders to promote new thinking on a global stage as we […]
Into its seventh year, WuXi Global Forum 2019 continues its tradition of bringing together thousands of leaders onsite and via live broadcasting to promote new thinking on a global stage.
Now in its sixth year, WuXi Global Forum 2018 takes place during the J.P. Morgan Healthcare Conference, with industry thought leaders discussing rapid advancements and changes impacting the industry, from […]
WuXi Global Forum 2017, now in its fifth year, brings together 1,000 industry leaders to find transformative models and solutions for patients, at a time when stakes are higher than […]
The life science industry is entering a renewed age of innovation in 2015. Collectively, we have delivered strong results on almost every front, buoyed by breakthrough therapies and scientific advancements. […]
To many, 2014 is a year of renewed energy and growth. Global partnerships at all levels are breaking down barriers to innovation, as the convergence of health and technology starts […]
2013 has been a great year in the world of pharmaceutical and biotech R&D. While we are still facing mounting productivity challenges, many have come to understand that any single […]
New state-of-the-art advanced therapies testing laboratories provide additional capacity for the growing cell and gene therapy industry. November 15, 2021 – Philadelphia. WuXi Advanced Therapies (WuXi ATU), a wholly owned […]
WuXi AppTec upgraded to an AA environmental, social and governance (ESG) rating by Morgan Stanley Capital International Shanghai, September 5, 2021 – WuXi AppTec (“the Company”) is pleased to announce […]
Revenue Up 45.7% Year-Over-Year to RMB10,537 Million Net Profit Attributable to Owners of the Company Up 55.8% Year-Over-Year to RMB2,675 Million Diluted EPS Up 46.8% Year-Over-Year to RMB0.91 Adjusted Non-IFRS […]
State-of-the-art facility significantly enhances WuXi STA’s drug product capacity in Europe while better enabling global customers New York & Shanghai, 3rd August, 2021: WuXi STA – a subsidiary of WuXi […]
WuXi STA bringing about 500 jobs to Middletown WILMINGTON, Del. (June 28, 2021) — WuXi STA and Delaware Prosperity Partnership today announced that WuXi STA, a leading Contract Development and […]
REGISTER NOW 21st Bio€quity Europe | Register Now and Receive 15% Discount, compliments of WuXi AppTec | May 17-19, 2021, Digital Event Can cross-border deals between Europe and China turn […]
Revenue Up 28.5% Year-over-Year to RMB16,535 Million Net Profit Attributable to Owners of the Company Up 59.6% Year-over-Year to RMB2,960 Million Diluted EPS Up 56.3% Year-over-Year to RMB1.25 Adjusted Non-IFRS […]
NEW YORK & SHANGHAI — Bristol Myers Squibb (NYSE: BMY) and WuXi STA – a subsidiary of WuXi AppTec – today announced that WuXi STA has agreed to purchase Bristol […]
December 1, 2020 – Philadelphia, PA and Munich, Germany – ViGeneron, a gene therapy company, and WuXi Advanced Therapies Inc. (WuXi ATU), a leading Contract, Testing, Development and Manufacturing Organization (CTDMO), […]
The new laboratory will increase industry testing capacity for cell and gene therapies, enabling faster and more effective development, manufacturing and delivery to patients. November 18, 2020 – Philadelphia, PA […]
WuXi AppTec Third-Quarter 2020 ResultsRevenue Growth Accelerated to 35.4% Year-Over-Year to RMB 4,583 MillionAdjusted Non-IFRS Net Profit Attributable to Owners of the Company Up 44.3% Year-Over-Year to RMB 958 MillionAdjusted Diluted Non-IFRS EPS Up 37.9% YoY to RMB0.40 WuXi […]
WuXi AppTec Second-Quarter 2020 Results Net Profit Attributable to Owners of the Company Up 111.0% YoY to RMB1,414 Millio Diluted EPS Up 110.3% YoY to RMB0.61 Adjusted Non-IFRS Net Profit Attributable […]